Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
10.1155/2014/856273 4 ChenJ.WongH.KoK
Extensive research has indicated that GPX3 is significantly downregulated in OC, and patients with elevated expression levels of this gene in their tumors are more likely to experience a poor prognosis
PlexusDx providers assess your genetic response profile to recommend the best next step, whether that's rotation, combination therapy, or lifestyle optimization
US$ 21.46
US$ 25.84
US$ 24.47
US$ 23.28
US$ 27.97
US$ 22.88
US$ 27.94
US$ 27.28
US$ 29.62
US$ 23.67
US$ 25.25
US$ 26.31
US$ 25.66
US$ 22.25
